膜细胞淋巴瘤:如何澄清围绕一线治疗的困惑?
Morgane Cheminant1,2, Elena Robin-Marieton2
1Adult Haematology department, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP).
Current opinion in oncology
|July 7, 2025
概括
新布鲁顿的氨酸激酶 (BTK) 抑制剂正在彻底改变一线地幔细胞淋巴瘤 (MCL) 治疗. 这些向疗法提供了改善的结果和降低的毒性,特别是对于年轻的患者,并为老年人提供无化疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床治疗学 临床治疗学
背景情况:
- 对地幔细胞淋巴瘤 (MCL) 的一线治疗已取得显著的进步,如高剂量cytarabine和自身干细胞移植等既定标准.
- 最近出现的布鲁顿氨酸激酶 (BTK) 抑制剂,向疗法和免疫疗法创造了复杂的治疗环境.
研究的目的:
- 审查地细胞淋巴瘤 (MCL) 一线治疗策略的最新进展.
- 为了解决由于新的治疗选择而出现的关于最佳第一线治疗方法的混乱问题.
主要方法:
- 审查最近的临床发现和新兴的治疗选择在MCL治疗.
- 分析新药对既定治疗模式的影响.
主要成果:
- 布鲁顿的氨酸激酶 (BTK) 抑制剂正在改变MCL治疗,改善结果并降低毒性.
- BTK 抑制剂正在成为年轻的MCL患者的第一线治疗必不可少的药物,可能会改变自身干细胞移植的作用.
- 向疗法为老年MCL患者提供了有希望的无化疗治疗途径.
结论:
- 随着治疗选择的不断扩大,可以在MCL中进行个性化治疗选择.
- 诊断时的预后分层对于定制治疗策略至关重要.
- 制定明确的指导方针是必要的,以应对治疗的复杂性,并优化患者的治疗结果.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


